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Abstract The potential association of human parvovi-
rus B19 infection with idiopathic thrombocytopenic
purpura (ITP) was studied. All 60 adult patients pres-
enting with ITP at the University Hospital Rotterdam –
Dijkzigt during a 12-year period (41 with acute ITP, 19
with chronic ITP) were included. Patient files were re-
trospectively analyzed. Stored serum samples were
tested for parvovirus B19-specific IgG and IgM anti-
bodies, and for parvovirus B19 DNA. In only one pa-
tient (1.7%) was evidence of recent B19 infection
found. Parvovirus B19 is not a frequent cause of adult
ITP and should be tested for only when there are other
indications of possible parvovirus B19 involvement.
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Introduction
The human parvovirus B19 replicates in erythroid pre-
cursor cells in the bone marrow. This causes lysis of in-
fected cells and, in the immunologically normal host, a
temporary arrest in erythropoiesis. Viral replication in
granulocytes, thrombocytes, and their precursors has
not been demonstrated, but there is transcription of the
viral genome [18]. The granulocytopenia and thrombo-
cytopenia that can occur with parvovirus B19 infection
are most probably due to the cytotoxic effect of the
NS1 protein of the virus [18].
In recent years, there have been reports of an asso-
ciation between parvovirus B19 infection and idiopat-
hic thrombocytopenic purpura (ITP) [10, 12]. However,
due to the small number of patients studied, the fre-
quency and clinical relevance of this association have
remained questionable. In one study, the results of par-
vovirus B19 serology on 61 serum samples from pa-
tients with recent ITP were described [10]. No nucleic
acid detection technique was used. Recent parvovirus
B19 infection was demonstrated in 5% of these serum
samples, which led to the conclusion that parvovirus
B19 serology should be included in virological investi-
gations in ITP. Here we report the results of a study on
parvovirus B19 infection among 60 adult patients with
ITP. Both serology and B19 DNA detection methods
were used.
Patients and methods
All patients presenting between March 1980 and August 1993 at
the Department of Hematology of the University Hospital Rot-
terdam with a diagnosis of idiopathic thrombocytopenic purpura
(ITP) were retrospectively analyzed. The diagnosis of ITP was
based on the following criteria: isolated thrombocytopenia, nor-
mal or increased numbers of bone marrow megakaryocytes, and
absence of splenomegaly. When patients presented within 6
months after the first symptoms of ITP they were considered to
have acute ITP, those who presented after 6 months were as-
signed to the group of chronic ITP.
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Table 1 Platelet numbers, platelet life span, and anti-platelet an-
tibodiesa in patients with acute and chronic ITP
Patients with
acute ITP
(np41)
Patients with
chronic ITP
(np19)
Mean platelet number
(range)
11.61!109/l
(1.00–42.00)
33.05!109/l
(3.00–89.00)
Mean platelet life span
(range)
{number tested}
0.8 days
(0.05–1.9)
{18}
1.4 days
(0.35–3.3)
{4}
Platelet-associated anti-
bodies 18/30 6/16
Circulating anti-platelet
antibodies 14/41 3/19
a IgG and/or IgM antibodies; data on anti-platelet antibodies are
presented as number positive/number tested
Blood samples were drawn from each patient at admission,
and sometimes one or more additional samples were obtained.
All patients were tested for anti-platelet antibodies, using an im-
munofluorescence technique as described previously [19]. In 22
cases the mean platelet life span was determined using indium
111-labeled autologous platelets [19]. Sera were kept frozen at
–20 7C. They were initially tested for recent infection with cytom-
egalovirus, Epstein-Barr virus, and hepatitis B virus as possible
causes of thrombocytopenia. Now they were tested for parvovirus
B19-specific IgG and IgM antibodies using an immunofluores-
cence assay [3] or an ELISA [16]. These tests appear to be of
comparable diagnostic value (unpublished data).
A parvovirus B19-specific polymerase chain reaction (PCR)
[15] was also performed on the sera. Spiking with parvovirus B19
containing serum was used to detect inhibition of the PCR by test
samples. This test can detect as few as 100 parvovirus B19 ge-
nome copies. In chronically infected immunocompromised pa-
tients, viremia with parvovirus B19 has a waxing and waning
course and can easily reach levels of 107 virus particles per millil-
iter serum, whereas in the immunologically normal host viremia
generally lasts for 2 months after primary infection, and up to
1014 virus particles per milliliter serum can be found [5, 7, 9,
14].
Results
There were 41 patients with acute ITP (14 male, 27 fe-
male), and 19 with chronic ITP (7 male, 12 female). The
mean age was 37.9 years (range 16–75 years) for pa-
tients with acute ITP and 39.3 years (range 16–78 years)
for patients with chronic ITP.
In 28 of the 41 patients with acute ITP, bleeding ten-
dency was the presenting symptom. Six of these 41
complained of fatigue and seven had had fever, sore
throat, or a “cold” prior to diagnosis of ITP.
Data on platelet number and life span and on anti-
platelet antibody testing are presented in Table 1.
Mean platelet life span was shortened in all 22 patients
tested, supporting the diagnosis of ITP. None of the pa-
tients had serologic evidence of recent infection with
cytomegalovirus, Epstein-Barr virus, or hepatitis B vi-
rus.
We tested 86 serum samples from all 60 patients for
B19-specific antibodies. On average, the period be-
tween first symptoms of acute ITP and the first serum
sample was 14.8 days (range 0–105 days, median 3
days). In 32 of the 60 patients (55%) parvovirus B19-
specific IgG without specific IgM was detected in the
initial serum sample, generally indicating past parvovi-
rus B19 infection (more than 3 months earlier). There
was no significant difference in the results of parvovirus
B19 serology between the patients with acute ITP and
those with chronic ITP (22/41 vs. 10/19 positive for spe-
cific IgG). Parvovirus B19-specific PCR was negative in
all sera, while none of them proved to inhibit the
PCR.
In one patient (2.4%) with acute ITP both specific
IgG and IgM were present in the initial serum sample.
A sample obtained 2 weeks later contained detectable
specific IgG, but not IgM. These findings indicate re-
cent parvovirus B19 infection. This 68-year-old female
patient presented with a 2-day history of bruises. She
had no other symptoms, and the family history was un-
remarkable. Physical examination revealed petechiae
and ecchymosis on the extremities, without other ab-
normalities. Laboratory studies revealed marked
thrombocytopenia (4!109/l), a shortened mean plate-
let life span (1.9 days; normal 8–10 days), and an in-
creased number of megakaryocytes in the bone mar-
row. All other hematologic values were within the nor-
mal range. Tests for platelet-associated and circulating
anti-platelet antibodies were negative. The patient was
treated with prednisone and recovered completely
within 3 months.
Discussion
The human parvovirus B19 is the cause of erythema in-
fectiosum, also known as fifth disease. Acute parvovi-
rus B19 infection can also cause arthralgia or arthritis
in adults (mainly women), aplastic crisis in chronic he-
molytic anemia, intrauterine fetal death, and various
other conditions. Chronic parvovirus B19 infection oc-
curs in patients with impaired humoral immunity, and
may lead to chronic anemia [7, 9].
Thrombocytopenia can occur in acute parvovirus
B19 infection. It has been attributed to the cytotoxic
effect of its protein NS1 [18]. Chronic thrombocytope-
nia as a result of chronic parvovirus B19 seems a logical
possibility in this condition, where NS1 is likely to be
continuously produced within the bone marrow. In a
recent case report, parvovirus B19 associated thrombo-
cytopenia lasting for about 1 month was described in an
elderly woman with a deficient immunological response
to parvovirus B19 [13]. Therefore, both acute and
chronic ITP might be caused by parvovirus B19 infec-
tion.
In the immunologically normal host, acute parvovi-
rus B19 infection can be detected by the presence of
viral DNA and of specific IgM antibodies. These anti-
bodies last approximately 3 months after the infection.
In the immunocompromised host, antibodies may not
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Table 2 Review of the recent literature on adult patients with purpura associated with human parvovirus B19 infection
Reference Patient
sex (age in years)
Symptoms Platelets
(!109/l)
1 / (?) Acute dermatosis with erythematous and purpuric lesions on hands and
feet (“gloves and socks”), fatigue, adenopathy, during B19 viremia
105
6 / (26) Purpuric plaques on buttocks, preceded by symmetric arthralgia in upper
and lower limbs, and followed by more widespread petechiae, mainly on
palms and soles; subsequently, Koplik spots in the mouth and a diffuse
morbiliform rash.
Initially, only B19-specific IgM detectable; later also specific IgG (no
serologic evidence of recent measles)
238
2 / (29) Fever up to 40 7C, myalgias, and purpura during B19 viremia in an
HIV-seropositive woman; full recovery with production of specific
antibodies
5
17 ? (33) Purpura, myalgia, arthralgia, arthritis, and fever (38.2 7C) during B19
viremia
193
8 / (36) Itching, pain, and swelling of hands and feet, followed by petechiae on
soft palate and on hands and feet (“glove and socks” distribution),
followed by desquamation; probably beginning during B19 viremia
315–192
13 / (73) Fever, arthralgia, and diarrhea, followed by petechiae and overt bleeding
in a previously healthy woman with persistent B19 infection, without
production of lasting specific antibodies
10
be produced in detectable quantities, and diagnosis re-
lies on the detection of parvovirus B19 DNA. In the
present series, the available techniques for demonstrat-
ing a recent parvovirus B19 infection in retrospectively
analyzed cases of ITP provided negative results in all
but a single case. In this patient, parvovirus B19 infec-
tion apparently presented as isolated thrombocytope-
nia. This frequency of one case in 60 analyzable ITP
patients, 41 of them with acute ITP, is even lower than
that found in another recent report [10].
Furthermore, the prevalence of B19-specific IgG in
this study group is not higher than in the general popu-
lation [4], and there was no difference in this respect
between patients with acute and those with chronic
ITP. This, in itself, suggests that there is no important
correlation between parvovirus B19 infection and ITP,
be it acute or chronic, in adult patients. In pediatric ITP
there may well be a correlation, especially since infec-
tion with the human parvovirus B19 usually occurs in
childhood [4]. Unfortunately, we had no access to sera
from cases of ITP in children. However, in one publica-
tion on acute ITP in childhood recent infection with hu-
man parvovirus B19 was suggested in 17 of 35 children
studied [11].
In order to assess the clinical presentation of
(thrombocytopenic) purpura associated with adult par-
vovirus B19 infection, a literature search was done. Ta-
ble 2 presents an overview of six recently published
cases of petechiae or purpura associated with proven
B19 infection. It is apparent from this overview that in
most patients the petechiae or purpura occurred during
B19 viremia, when specific DNA or IgM are readily de-
tectable. Also, the clinical presentation varies widely.
In five of the six patients other signs indicative of B19
infection were present, such as arthralgia, myalgia, and
erythematous rash. Of the six patients, three do not fit
our definition of ITP because they were not thrombo-
cytopenic.
The human parvovirus B19 seems to be at best a mi-
nor causative factor in adult ITP, but it may be impor-
tant in pediatric ITP. It stands to reason that in adult
patients with ITP, parvovirus B19 infection need be
considered only in cases where other symptoms sugges-
tive of this infection are present in the patients or their
household contacts.
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